logo
Share SHARE
FONT-SIZE Plus   Neg

BioLineRx Announces Extension Of Patent For BCM By USPTO - Quick Facts

BioLineRx (BLRX: Quote) said an Issue Notification has been received from the United States Patent and Trademark Office granting 1,787 days of Patent Term Adjustment for the patent claiming the composition of BCM (BL-1040), a novel medical device for prevention of cardiac remodeling following an acute myocardial infarction.

Accordingly, the term of this patent will now extend through at least the end of April 2029, which is almost three years longer than previously reported by the company. Additional patents claiming the BL-1040 composition and its use for the treatment of ventricular remodeling and congestive heart failure due to acute myocardial infarction are granted or pending in Europe, Japan, Canada, Korea, Mexico, Israel, India, China and Australia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Video-game retailer GameStop Corp. said Thursday after the markets closed that its fourth quarter profit rose 11% from last year, as better cost control helped offset a 5.6% decrease in sales. However, the company's quarterly earnings per share, excluding item, came in below analysts' expectations as did its quarterly sales. The Villages, a serene retirement hometown in Florida has been designated as the fastest-growing metro in the U.S. for the second consecutive year, as per Census estimates released on Thursday. A federal government agency has outlined proposals to regulate payday loans as part of efforts to curb debt traps and provide reprieve to cash-strapped borrowers, while ensuring credit supply is not hampered.
comments powered by Disqus
RELATED NEWS
Trade BLRX now with 
Follow RTT